PN 162
Alternative Names: MC1R agonist - Confo Therapeutics; Melanocortin type 1 receptor agonist - Confo Therapeutics; PN-162Latest Information Update: 08 Oct 2024
At a glance
- Originator Confo Therapeutics
- Class Antifibrotics
- Mechanism of Action Melanocortin type 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Fibrosis; Immunological disorders
Most Recent Events
- 31 Jul 2024 Confo Therapeutics has patent protection for Confo® technology platform in more than 10 patent families worldwide, prior to July 2024 (Confo Therapeutics website, July 2024)
- 26 Jul 2024 Early research in Fibrosis in Belgium (unspecified route)
- 26 Jul 2024 Early research in Immunological disorders in Belgium (unspecified route)